πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 112 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12239692

Adeno-associated virus factor VIII vectors

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12233106

C-type natriuretic peptide variants to treat skeletal dysplasia in children

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12214015

Use of c-type natriuretic peptide variants to treat osteoarthritis

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12188058

Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses the

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12076372

Use of C-type natriuretic peptide variants to treat skeletal dysplasia

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11918633

Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11911446

Use of C-type natriuretic peptide variants to treat skeletal dysplasia

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11821008

Liver targeting adeno-associated viral vectors

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11739345

Methods of treating phenylketonuria

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11690898

Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic for

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11590204

Use of C-type natriuretic peptide variants to treat skeletal dysplasia

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11584780

Adeno-associated virus capsid proteins

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11505790

Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using comp

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11406690

Adeno-associated virus factor VIII vectors

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11384055

Glycolate oxidase inhibitors for the treatment of disease

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11358932

N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosyl

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11351231

Lysosomal targeting peptides and uses thereof

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11345904

Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses th

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11254725

Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11229687

TPP-1 formulations and methods for treating CLN2 disease

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11202819

Use of C-type natriuretic peptide variants to treat osteoarthritis

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11040088

Delivery of therapeutic compounds to the brain and other tissues

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10934534

Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses the

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10851058

Histone deacetylase inhibitors

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted